BackAtyr Pharma Overview
Atyr Pharma Inc

Atyr Pharma Target Price

Analysts' average 12-month price target for Atyr Pharma is $35.

Get informed when a big investor buys or sells

+ Follow

Share Price

$42.02

Average Target Price

$34.5017.9% downside

6 analysts in the last 4 months

High: $40 | Low: $30

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-04Deutsche BankKunal Madhukar$404.8% downsideOpen
2026-08-04Robert W. Baird$3223.8% downsideOpen
2026-08-04Piper SandlerRoss Sandler$3711.9% downsideOpen
2026-08-04William Blair$3321.5% downsideOpen
2026-08-04Goldman SachsEric Sheridan$3516.7% downsideOpen
2026-05-14Deutsche Bank$3028.6% downsideOpen
2026-05-07Robert W. BairdColin Sebastian$2638.1% downsideOpen
2026-05-07Barclays$2735.7% downsideOpen
2026-02-24Deutsche BankLee Horowitz$2345.3% downsideOpen
2026-02-23Robert W. Baird$1857.2% downsideOpen
2026-02-23Goldman Sachs$3321.5% downsideOpen
2026-02-23Piper SandlerRoss Sandler$2052.4% downsideOpen
2026-02-23RBC Capital$2150% downsideOpen

Atyr Pharma (LIFE) FAQ

Atyr Pharma (LIFE) currently reports a target price of $35. Use the charts on this page to explore Atyr Pharma's target price history and peer comparisons.

Analysts' average 12-month price target for Atyr Pharma is $35, about 17.9% downside from the current share price of $42.02. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $35, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Atyr Pharma, and consider following LIFE for alerts when major investors trade the stock.

Atyr Pharma is classified in the Healthcare sector. On target price, it currently shows $35. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LIFE with unrelated industries.